We are analyzing https://link.springer.com/article/10.1007/s10787-018-0490-0.

Title:
Efficacy of punarnavine in restraining organ-specific tumour progression in 4T1-induced murine breast tumour model | Inflammopharmacology
Description:
Most of the breast cancer deaths occur when cancer cells depart from their tumour of origin and spread systemically and colonise distant organs. The present study was to find out whether punarnavine, the quinolizidine alkaloid, with already proven antimetastatic effect on spontaneous B16F10 pulmonary metastasis has got any effect on a drastic organ-specific breast cancer spread. For the study, we selected a syngenic mouse 4T1 breast tumour model that mimics stage four of human breast cancer. The metastatic progression of 4T1 to lymph nodes, lungs, and liver was reduced by punarnavine (40 mg/kg body weight) administration in BALB/c mice. This was evident from the histopathology of these organs as well as from the reduction in the metastatic cell density of cultured 6-thioguanine-resistant 4T1 cells in the punarnavine-treated group compared to the control group. There was also a significant (p < 0.0001) inhibition of the primary breast tumour growth in the orthotopic site of induction with a simultaneous increase (p < 0.0001) in the life span of treated animals. The assessment of biochemical parameters such as hydroxyproline, hexosamine, uronic acid, sialic acid and γ-glutamyl transferase and the analysis of various cytokines VEGF, IL-1β, TNF-α and GM-CSF showed a similar pattern of reduction in punarnavine (p < 0.0001) treated group compared to the control group. The gene expression study revealed the inhibitory effect of punarnavine on the major genes MMP-2, MMP-9, TIMP-1, TIMP-2 and VEGF involved in the metastatic process. These findings undeniably proved the potential of this quinolizidine alkaloid in combating breast tumour development and its progression in the studied murine model.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We can't figure out the monetization strategy.

Not all websites are made for profit; some exist to inform or educate users. Or any other reason why people make websites. And this might be the case. Link.springer.com has a secret sauce for making money, but we can't detect it yet.

Keywords {🔍}

pubmed, article, google, scholar, cas, cancer, breast, central, punarnavine, tumour, metastasis, cell, metastatic, cells, mouse, clin, kuttan, alkaloid, acid, research, progression, model, diffusa, nature, privacy, cookies, organspecific, matrix, boerhavia, models, biol, tumor, content, publish, search, george, study, group, sialic, vegf, access, drug, metalloproteinase, evaluation, activity, mammary, carcinoma, nat, rev, data,

Topics {✒️}

month download article/chapter triple-negative breast cancer organ-specific colonization studied murine model inflammation-induced cell migration cyclooxygenase-dependent tumor growth 40 mg/kg body weight analytical de-o-acetylation interleukin-1β tnf-α article inflammopharmacology aims inhibiting nf-kappab signaling mouse breast tumours full article pdf metastatic tumour foci gilcy george 4t1 cell line cytokines vegf punarnavine-treated group compared metastatic breast carcinoma privacy choices/manage cookies epithelial–mesenchymal transition cancer cells depart breast cancer metastasis human breast cancer drug discovery perspective b16f-10 melanoma cells sialic acid assay girija kuttan anticancer drug discovery il-17-producing γδ reaction-rate method børresen-dale a anti-metastatic potential bmc cancer 14 boerhavia diffusa linn treated group compared metalloproteinase-2 expression metastatic progression european economic area γ-glutamyl transferase gm-csf showed major genes mmp-2 findings undeniably proved check access action abbreviations dmem den brok mh clinical practice guidelines chiang ac positive feedback loop regulating collagen deposition

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Efficacy of punarnavine in restraining organ-specific tumour progression in 4T1-induced murine breast tumour model
         description:Most of the breast cancer deaths occur when cancer cells depart from their tumour of origin and spread systemically and colonise distant organs. The present study was to find out whether punarnavine, the quinolizidine alkaloid, with already proven antimetastatic effect on spontaneous B16F10 pulmonary metastasis has got any effect on a drastic organ-specific breast cancer spread. For the study, we selected a syngenic mouse 4T1 breast tumour model that mimics stage four of human breast cancer. The metastatic progression of 4T1 to lymph nodes, lungs, and liver was reduced by punarnavine (40 mg/kg body weight) administration in BALB/c mice. This was evident from the histopathology of these organs as well as from the reduction in the metastatic cell density of cultured 6-thioguanine-resistant 4T1 cells in the punarnavine-treated group compared to the control group. There was also a significant (p < 0.0001) inhibition of the primary breast tumour growth in the orthotopic site of induction with a simultaneous increase (p < 0.0001) in the life span of treated animals. The assessment of biochemical parameters such as hydroxyproline, hexosamine, uronic acid, sialic acid and γ-glutamyl transferase and the analysis of various cytokines VEGF, IL-1β, TNF-α and GM-CSF showed a similar pattern of reduction in punarnavine (p < 0.0001) treated group compared to the control group. The gene expression study revealed the inhibitory effect of punarnavine on the major genes MMP-2, MMP-9, TIMP-1, TIMP-2 and VEGF involved in the metastatic process. These findings undeniably proved the potential of this quinolizidine alkaloid in combating breast tumour development and its progression in the studied murine model.
         datePublished:2018-05-17T00:00:00Z
         dateModified:2018-05-17T00:00:00Z
         pageStart:701
         pageEnd:712
         sameAs:https://doi.org/10.1007/s10787-018-0490-0
         keywords:
            Breast cancer
            4T1 mouse tumour model
            Punarnavine
            Organ-specific tumour progression
            Cytokines
            Matrix metalloproteinase
            Pharmacology/Toxicology
            Immunology
            Rheumatology
            Gastroenterology
            Dermatology
            Allergology
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig1_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig2_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig3_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig4_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig5_HTML.gif
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig6_HTML.gif
         isPartOf:
            name:Inflammopharmacology
            issn:
               1568-5608
               0925-4692
            volumeNumber:27
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Springer International Publishing
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Gilcy George Kallivalappil
               affiliation:
                     name:Amala Cancer Research Centre (Affiliated to the University of Calicut)
                     address:
                        name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Girija Kuttan
               affiliation:
                     name:Amala Cancer Research Centre (Affiliated to the University of Calicut)
                     address:
                        name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Efficacy of punarnavine in restraining organ-specific tumour progression in 4T1-induced murine breast tumour model
      description:Most of the breast cancer deaths occur when cancer cells depart from their tumour of origin and spread systemically and colonise distant organs. The present study was to find out whether punarnavine, the quinolizidine alkaloid, with already proven antimetastatic effect on spontaneous B16F10 pulmonary metastasis has got any effect on a drastic organ-specific breast cancer spread. For the study, we selected a syngenic mouse 4T1 breast tumour model that mimics stage four of human breast cancer. The metastatic progression of 4T1 to lymph nodes, lungs, and liver was reduced by punarnavine (40 mg/kg body weight) administration in BALB/c mice. This was evident from the histopathology of these organs as well as from the reduction in the metastatic cell density of cultured 6-thioguanine-resistant 4T1 cells in the punarnavine-treated group compared to the control group. There was also a significant (p < 0.0001) inhibition of the primary breast tumour growth in the orthotopic site of induction with a simultaneous increase (p < 0.0001) in the life span of treated animals. The assessment of biochemical parameters such as hydroxyproline, hexosamine, uronic acid, sialic acid and γ-glutamyl transferase and the analysis of various cytokines VEGF, IL-1β, TNF-α and GM-CSF showed a similar pattern of reduction in punarnavine (p < 0.0001) treated group compared to the control group. The gene expression study revealed the inhibitory effect of punarnavine on the major genes MMP-2, MMP-9, TIMP-1, TIMP-2 and VEGF involved in the metastatic process. These findings undeniably proved the potential of this quinolizidine alkaloid in combating breast tumour development and its progression in the studied murine model.
      datePublished:2018-05-17T00:00:00Z
      dateModified:2018-05-17T00:00:00Z
      pageStart:701
      pageEnd:712
      sameAs:https://doi.org/10.1007/s10787-018-0490-0
      keywords:
         Breast cancer
         4T1 mouse tumour model
         Punarnavine
         Organ-specific tumour progression
         Cytokines
         Matrix metalloproteinase
         Pharmacology/Toxicology
         Immunology
         Rheumatology
         Gastroenterology
         Dermatology
         Allergology
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig1_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig2_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig3_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig4_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig5_HTML.gif
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1007%2Fs10787-018-0490-0/MediaObjects/10787_2018_490_Fig6_HTML.gif
      isPartOf:
         name:Inflammopharmacology
         issn:
            1568-5608
            0925-4692
         volumeNumber:27
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Springer International Publishing
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Gilcy George Kallivalappil
            affiliation:
                  name:Amala Cancer Research Centre (Affiliated to the University of Calicut)
                  address:
                     name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Girija Kuttan
            affiliation:
                  name:Amala Cancer Research Centre (Affiliated to the University of Calicut)
                  address:
                     name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Inflammopharmacology
      issn:
         1568-5608
         0925-4692
      volumeNumber:27
Organization:
      name:Springer International Publishing
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Amala Cancer Research Centre (Affiliated to the University of Calicut)
      address:
         name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
         type:PostalAddress
      name:Amala Cancer Research Centre (Affiliated to the University of Calicut)
      address:
         name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Gilcy George Kallivalappil
      affiliation:
            name:Amala Cancer Research Centre (Affiliated to the University of Calicut)
            address:
               name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
               type:PostalAddress
            type:Organization
      name:Girija Kuttan
      affiliation:
            name:Amala Cancer Research Centre (Affiliated to the University of Calicut)
            address:
               name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
      name:Department of Immunology, Amala Cancer Research Centre (Affiliated to the University of Calicut), Thrissur, India
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(184)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

4.16s.

LINK . SPRINGER . COM {}